These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12724854)

  • 1. The reversal of multidrug resistance: an update.
    Kellen JA
    J Exp Ther Oncol; 2003; 3(1):5-13. PubMed ID: 12724854
    [No Abstract]   [Full Text] [Related]  

  • 2. Multidrug resistance reversal agents.
    Robert J; Jarry C
    J Med Chem; 2003 Nov; 46(23):4805-17. PubMed ID: 14584929
    [No Abstract]   [Full Text] [Related]  

  • 3. Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1.
    Gillet JP; Gottesman MM
    Drug Resist Updat; 2012; 15(1-2):2-4. PubMed ID: 22465109
    [No Abstract]   [Full Text] [Related]  

  • 4. Obinutuzumab in multidrug-resistant hairy cell leukemia.
    Bohn JP; Willenbacher E; Steurer M
    Ann Hematol; 2016 Jan; 95(2):351-2. PubMed ID: 26446506
    [No Abstract]   [Full Text] [Related]  

  • 5. Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?
    Bourquin JP; Bornhauser B
    Expert Rev Hematol; 2010 Aug; 3(4):369-72. PubMed ID: 21083025
    [No Abstract]   [Full Text] [Related]  

  • 6. Nanomedicine against multidrug resistance in cancer treatment.
    Gao J; Feng SS; Guo Y
    Nanomedicine (Lond); 2012 Apr; 7(4):465-8. PubMed ID: 22471716
    [No Abstract]   [Full Text] [Related]  

  • 7. Research Progress in Reversal of Tumor Multi-drug Resistance via Natural Products.
    Guo Q; Cao H; Qi X; Li H; Ye P; Wang Z; Wang D; Sun M
    Anticancer Agents Med Chem; 2017 Nov; 17(11):1466-1476. PubMed ID: 29034843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy.
    Dlugosz A; Janecka A
    Curr Pharm Des; 2016; 22(30):4705-4716. PubMed ID: 26932159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance reversal activity of key ningalin analogues.
    Soenen DR; Hwang I; Hedrick MP; Boger DL
    Bioorg Med Chem Lett; 2003 May; 13(10):1777-81. PubMed ID: 12729663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells.
    Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R
    Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achilles heels and Trojan horses against drug-resistant tumor cells.
    Park K
    J Control Release; 2011 Jan; 149(2):91. PubMed ID: 21167115
    [No Abstract]   [Full Text] [Related]  

  • 12. Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer.
    Shankaraiah N; Nekkanti S; Ommi O; P S LS
    Curr Med Chem; 2019; 26(39):7059-7080. PubMed ID: 29637849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer.
    Li Y; Zhang HB; Huang WL; Li YM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3652-5. PubMed ID: 18502125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.
    Sawicka M; Kalinowska M; Skierski J; Lewandowski W
    J Pharm Pharmacol; 2004 Sep; 56(9):1067-81. PubMed ID: 15324475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
    Zhang Q; Li F
    Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cyclic hydroxamic acids as chemosensitizers in cytostatic therapy].
    Konovalova NP; Vystoron IV; Sashenkova TE; Klimanova EN; Mishchenko DV; Allaiarova UIu; Goncharova SA; Raevskaia TA; Iakushchenko TN; Cherniak AV
    Vopr Onkol; 2013; 59(5):620-2. PubMed ID: 24260891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and multidrug resistance reversal activity evaluation of 8-oxocoptisine derivatives.
    Wu JB; Lei F; Cui XJ; He Y; Hai L; Zhang J; Wu Y
    Med Chem; 2012 Jul; 8(4):742-8. PubMed ID: 22548337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.
    Ojima I; Borella CP; Wu X; Bounaud PY; Oderda CF; Sturm M; Miller ML; Chakravarty S; Chen J; Huang Q; Pera P; Brooks TA; Baer MR; Bernacki RJ
    J Med Chem; 2005 Mar; 48(6):2218-28. PubMed ID: 15771464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport.
    Patel A; Li TW; Anreddy N; Wang DS; Sodani K; Gadhia S; Kathawala R; Yang DH; Cheng C; Chen ZS
    Pharmacol Res; 2017 Jul; 121():184-193. PubMed ID: 28455266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
    Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
    Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.